Published in Lab Law Weekly, March 26th, 2010
Total progesterone sales increased 23% with domestic sales of CRINONE® 8% (progesterone gel) increasing 31% and international sales increasing 24%, partially offset by a decline in sales of PROCHIEVE® 8% (progesterone gel), as compared to the fourth quarter of 2008.
Net loss of $5.4 million ($0.09 per basic and diluted share) compared to a net loss of $3.5 million ($0.06 per basic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.